Live feed
·
NEWSReleasevia Quantisnow
MIRA Pharmaceuticals Inc. logo

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

ByQuantisnow·Wall Street's wire, on your screen.
MIRA· MIRA Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRA (MIRA Pharmaceuticals Inc.) and more on Quantisnow.